Risperidone has been approved by the Food and Drug Administration for the treatment of schizophrenia in the adolescent population. This new indication has been a result of data obtained from two pivotal double-blind trials with supplemental information from open-label and retrospective trials. This brief article provides an overview of risperidone's pharmacological profile followed by information on the double-blind trials that have resulted in the approval of risperidone for the treatment of adolescent schizophrenia.
Copyright 2009 Prous Science, S.A.U. or its licensors. All rights reserved.